The Government of the United States of America, Patent applications |
Patent application number | Title | Published |
20130172729 | ACTIVE ADAPTIVE DETUNING SYSTEMS AND METHODS FOR INTERVENTIONAL DEVICES - Active MRI compatible interventional devices, such as catheters, include at least one RF antenna so that they are visible under MRI analysis. However, metallic structures within intravascular devices may heat up significantly during interventional MRI procedures due to eddy current formation over the conductive transmission lines. The electrical field coupling that occurs between interventional devices and RF signals depend on the position and orientation of interventional device within the bore and the insertion length of the interventional device. The system detects an induced current signal during RF transmission phase and selectively adjusts the impedance value associated with the interventional device by using a varactor and integrated circuit components in such a manner that the currents induced in the interventional device are below a threshold current level, thereby controlling current levels and heating in the interventional device. | 07-04-2013 |
20090283693 | INTEGRALLY GATED CARBON NANOTUBE IONIZER DEVICE - Described herein is a field ionization and electron impact ionization device consisting of carbon nanotubes with microfabricated integral gates that is capable of producing short pulses of ions. | 11-19-2009 |
20090036791 | Neuronal Avalanche Assay - Method and system for determining a cognitive enhancement and/or anti-epileptic effect comprising: detecting synchronized neuronal activity in neuronal tissue ( | 02-05-2009 |
20080260687 | SPECIFIC BINDING AGENTS FOR KSHV vIL-6 THAT NEUTRALIZE A BIOLOGICAL ACTIVITY - A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent. A decrease in the binding of vIL-6 to the receptor component in the presence of the agent indicates that the agent is effective for treating the KSHV-associated disorder. | 10-23-2008 |